{
    "paper_id": "PMC7203542",
    "metadata": {
        "title": "Circumnavigating the challenges of COVID-19 in oncology",
        "authors": [
            {
                "first": "Thorsten",
                "middle": [],
                "last": "Fuereder",
                "suffix": "",
                "email": "thorsten.fuereder@meduniwien.ac.at",
                "affiliation": {}
            },
            {
                "first": "Eberhard",
                "middle": [],
                "last": "Gunsilius",
                "suffix": "",
                "email": "eberhard.gunsilius@i-med.ac.at",
                "affiliation": {}
            },
            {
                "first": "Rupert",
                "middle": [],
                "last": "Bartsch",
                "suffix": "",
                "email": "rupert.bartsch@meduniwien.ac.at",
                "affiliation": {}
            },
            {
                "first": "Wolfgang",
                "middle": [],
                "last": "Hilbe",
                "suffix": "",
                "email": "wolfgang.hilbe@wienkav.at",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "\nThe SARS CoV\u20112 crisis is also a crisis for patients suffering malignant disease. Besides their risk of a life-threatening disease on the one hand with commonly immunosuppressive treatments on the other hand they are of special risk if they come into contact with this virus infection.Our patients know about this doubled risk. The psychological burden of this situation posed on them cannot be overestimated.The primary task oncology is balancing patient-specific risk factors against treatment-induced side effects with a special focus on immunosuppression.Patients with haematological malignancies may well be the most threatened patient population as many are heavily immunosuppressed due to the underlying disease and due to neutropenia-inducing treatment strategies.Lung cancer patients represent another highly vulnerable group with special needs during the current SARS CoV\u20112 pandemic. Cumulative risk factors for severe COVID-19 infections can regularly be detected like pre-existing pulmonary diseases, cardiovascular disease, smoking related lung damage and older age.The broad application of checkpoint inhibitor (CPI) therapies in medical oncology with their risk of CPI-induced pneumonitis has to be discussed on an individual basis.The threat posed by the SARS CoV\u20112 pandemic can be reduced through several actions on a hospital and department level.On a day per day decision we have to balance the risk and benefits of treating our patients or better delaying any specific therapy. The risk of a COVID-19 infection depends on specific regional actual infection rates and this knowledge has to be integrated into our recommendations.\n",
            "cite_spans": [],
            "section": "Key messages",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a\u00a0report of 72\u202f314 cases from the Chinese center for disease control and prevention",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "JM",
                    "middle": [],
                    "last": "McGoogan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "323",
            "issn": "13",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.2648"
                ]
            }
        },
        "BIBREF1": {
            "title": "Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Martins",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Sofiya",
                    "suffix": ""
                },
                {
                    "first": "GP",
                    "middle": [],
                    "last": "Sykiotis",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Nat Rev Clin Oncol",
            "volume": "16",
            "issn": "9",
            "pages": "563-580",
            "other_ids": {
                "DOI": [
                    "10.1038/s41571-019-0218-0"
                ]
            }
        },
        "BIBREF2": {
            "title": "Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Keam",
                    "suffix": ""
                },
                {
                    "first": "CK",
                    "middle": [],
                    "last": "Kang",
                    "suffix": ""
                },
                {
                    "first": "KI",
                    "middle": [],
                    "last": "Jun",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Clin Infect Dis",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1093/cid/ciz1092"
                ]
            }
        },
        "BIBREF3": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a\u00a0global pandemic",
            "authors": [
                {
                    "first": "TP",
                    "middle": [],
                    "last": "Hanna",
                    "suffix": ""
                },
                {
                    "first": "GA",
                    "middle": [],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "CM",
                    "middle": [],
                    "last": "Booth",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Rev Clin Oncol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1038/s41571-020-0362-6"
                ]
            }
        },
        "BIBREF5": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bersanelli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Immunotherapy",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.2217/imt-2020-0067"
                ]
            }
        },
        "BIBREF10": {
            "title": "Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a\u00a0pictorial review",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Radiol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1007/s00330-020-06801-0"
                ]
            }
        },
        "BIBREF11": {
            "title": "Management of pulmonary toxicity associated with immune checkpoint inhibitors",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Delaunay",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Prevot",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Collot",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Guilleminault",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Didier",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mazieres",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Eur Respir Rev",
            "volume": "28",
            "issn": "154",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1183/16000617.0012-2019"
                ]
            }
        }
    }
}